Health Care · Biological Products, (No Diagnostic Substances)

MAZE Maze Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 184229588 filings
Russell 2000

MAZE at a glance

Maze Therapeutics, Inc. (MAZE, SEC CIK 1842295) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2024 (FY2024), Maze Therapeutics, Inc. (MAZE) reported revenue of $167.5 million and net income of $52.2 million. Diluted EPS was $1.25.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Maze Therapeutics, Inc. (MAZE) shares worth $365.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Coloma Jason V on November 2, 2026 of 26,563 shares at $30.09 per share.
  • In the last 90 days, MAZE insiders reported 0 open-market purchases ($0) and 30 open-market sales ($5.8M) on Form 4, a net sale of $5.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2024
$167.5M
10-K XBRL
Insiders · 90 days
0 buys · 30 sells
Net −$5.8M
13F holders
24 funds
$365.3M · −1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY; nine-month license revenue $20.0M vs $0
  • Operating margin -107.3% vs -112.9% YoY, based on operating losses of $51.5M and $33.0M
  • MZE829 R&D spending $7.1M, MZE782 $5.6M, up $2.8M and $3.5M YoY
  • Cash, equivalents and marketable securities $477.0M; operating cash use $87.0M for nine months
  • Outlook: additional capital needed; MZE782 PKU data expected 2027 and MZE829 pivotal trial planned first half 2027

Risk Factors

  • Newly emphasized supply-chain risk: BIOSECURE Act signed December 2025 could restrict WuXi relationships if designated a biotechnology company of concern
  • Regulatory risk: CMS GLOBE model begins January 1, 2027, potentially requiring incremental Medicare Part B rebates tied to international prices
  • Clinical risk: MZE782 Phase 2 PKU trial initiated August 2026, with topline data expected in 2027
  • Operational risk: MZE829 pivotal trial planned first half of 2027, subject to regulatory feedback
  • Financial risk: $477.0 million cash, cash equivalents and marketable securities expected to fund operations for at least one year

AI summary of the MAZE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 net loss widened to $48.0M, or $0.79 per share, from $30.1M, reflecting accelerated clinical investment
  • Cash, equivalents and marketable securities reached $477.0M, supporting projected operations into 2029
Filed Oct 16, 2026Full analysis →

Item 3.02: Unregistered Sales of Equity Securities

  • Maze exchanged 2,776,007 common shares for pre-funded warrants exercisable at $0.001 per share
  • Outstanding shares decreased to 53,931,889 after the exchange, reducing immediately outstanding equity

Item 1.01: Entry into a Material Definitive Agreement

  • Item 1.01 points investors to Item 3.02 for the substantive transaction details
  • Material agreement implications depend on the securities issuance or funding terms described under Item 3.02
Filed Aug 17, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Dr. Johnson and Dr. Kornowski appointed to Maze Therapeutics’ Board
  • Board additions may influence governance, strategic direction and oversight

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board additions: Paula A. Johnson and Sophie Kornowski appointed as Class III and Class I directors, respectively
  • Dr. Kornowski joins audit and compensation committees, strengthening biopharma, investment and business-development expertise

Item EX-99.1: Item EX-99.1

  • Paula Johnson and Sophie Kornowski appointed to Maze’s Board, strengthening clinical, biopharmaceutical, partnering, and M&A expertise
  • MZE829 additional AMKD data expected in late 2026 or early 2027

AI summaries of MAZE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MAZE

Don't miss the next MAZE filing

  • Alerts as it files. A push when MAZE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MAZE, by share count.
  • Ask anything. An AI agent that reads every MAZE filing and answers with sources.

MAZE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Coloma Jason VSellNov 2, 2026$30.09
Coloma Jason VSellNov 2, 2026$31.05
Coloma Jason VSellNov 2, 2026$30.12
Coloma Jason VSellNov 2, 2026$30.91
Dandekar AtulMOct 29, 2026$10.42
Dandekar AtulMOct 29, 2026-
Dandekar AtulMOct 29, 2026$10.42
Dandekar AtulSellOct 29, 2026$32.07

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$167.5M-
Operating Income-$57.6M-$142.9M
Net Income-$52.2M-$131.1M
Op. Margin-34.4%-
Net Margin-31.2%-
Balance Sheet
Total Assets-$240.5M$397.1M
Equity-$373.8M-$311.2M$355.0M
ROE--16.8%-36.9%
Per Share
EPS-$1.25$-3.05
Cash Flow
Operating CF-$76.0M-$111.9M
CapEx-$1.1M$794K

Source: XBRL data in Maze Therapeutics, Inc. (MAZE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MAZE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MAZE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$365.3M
Q2 202625$384.3M
Q1 202629$284.2M
Q4 202525$349.2M
Q3 202519$178.0M
Q2 202514$53.5M
Q1 202514$47.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MAZE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Nov 4, 2026--
4Oct 30, 2026--
8-KOct 16, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 1, 2026--
4Sep 8, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 31, 2026--
4Aug 17, 2026--
8-KAug 17, 2026Analysis-
4Aug 17, 2026--
4Aug 14, 2026--
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
4Aug 5, 2026--

Related Health Care companies

All Health Care →

MAZE SEC filings: frequently asked questions

Are MAZE insiders buying or selling?

In the last 90 days, Maze Therapeutics, Inc. (MAZE) officers, directors and 10% owners reported no open-market purchases and 30 open-market sales worth $5.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MAZE stock?

As of September 30, 2026, the largest Maze Therapeutics, Inc. (MAZE) holders among the 13F filers tracked by SignalX were BlackRock ($100.9 million), Vanguard Capital Management LLC ($51.1 million), Citadel Advisors LLC ($42.9 million), Alphabet Inc ($37.7 million), JPMorgan Chase & Co ($32.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MAZE's revenue in fiscal year 2024?

For the fiscal year ended December 31, 2024 (FY2024), Maze Therapeutics, Inc. (MAZE) reported revenue of $167.5 million and net income of $52.2 million. Diluted EPS was $1.25. The figures come from the XBRL data in the 10-K.

What did MAZE report in its latest 8-K?

Maze Therapeutics, Inc. (MAZE) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest MAZE SEC filings?

Maze Therapeutics, Inc. (MAZE) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 4, 2026.

What is MAZE's SEC CIK number?

Maze Therapeutics, Inc. (MAZE)'s SEC Central Index Key (CIK) is 1842295. EDGAR lists every MAZE filing under that number.

Ask anything about MAZE

The research agent reads MAZE's filings, financials, insider trades and 13F holders, then answers with sources.